PMFA
ADMS

Plante Moran Financial Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Plante Moran Financial Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-47
Closed -$1K – 1012
2016
Q2 		$1K Hold
47
– – ﹤0.01% 879
2016
Q1 		$1K Buy
+47
New +$792 ﹤0.01% 823

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
BS
Bow Street New York $52.4M AUM 2.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $15.8B AUM 1.29% 1-Year Est. Return

Plante Moran Financial Advisors's ADMS Position: Q3 2016 in Review

Plante Moran Financial Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q3 2016, closing a stake of 47 shares — an estimated $1K sold.

Plante Moran Financial Advisors first reported a position in ADMS in Q1 2016 and held it in 2 quarters. The position peaked at $1K in Q2 2016. 81 funds tracked by Wall St. Rank hold ADMS as of Q3 2016.

  • Plante Moran Financial Advisors reported no remaining Adamas Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 47 Adamas Pharmaceuticals shares in Q3 2016, an estimated $1K.
  • Plante Moran Financial Advisors first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Plante Moran Financial Advisors's Adamas Pharmaceuticals position peaked at $1K in Q2 2016.
  • 81 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2016.

Based on Plante Moran Financial Advisors's 13F filing for Q3 2016, filed 3 Nov 2016.